drugset / Trial / NCT00308048
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients with HCV genotype 2 or 3 infection who have a rapid virological response to treatment are randomised to either 14 or 24 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.
Timeline
- Start
- 2004-03
- Primary completion
- —
- Completion
- 2006-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 1.5 ug/kg | — |
| Subject | Ribavirin | Small molecule | 800 mg | — |
| Subject | Ribavirin | Small molecule | 1400 mg | — |